Brain and Central Nervous System Tumors Clinical Trial
Official title:
Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.
Verified date | July 2018 |
Source | European Organisation for Research and Treatment of Cancer - EORTC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as temozolomide, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether radiation therapy is more effective when given together with temsirolimus or
temozolomide in treating patients with glioblastoma.
PURPOSE: This randomized phase II trial is studying giving radiation therapy together with
temsirolimus to see how well it works compared with giving radiation therapy together with
temozolomide in treating patients with newly diagnosed glioblastoma.
Status | Completed |
Enrollment | 111 |
Est. completion date | March 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed (by open brain biopsy or from a neurosurgical resection of the tumor) supratentorial glioblastoma multiforme (GBM) - WHO grade IV disease - Newly diagnosed disease - Must provide demonstration of an unmethylated MGMT-promoter - At least 2 weeks and no more than 6 weeks since surgery or open biopsy - Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination, and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K) PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy = 12 weeks - WBC = 3.0 x 10^9/L - Absolute neutrophil count = 1.5 x10^9/L - Platelet count = 75.0 x 10^9/L - Hemoglobin = 10.0 g/dL - Bilirubin = 1.5 times the upper limit of normal (ULN) - Alkaline phosphatase = 2.5 x ULN - AST and/or ALT = 2.5 x ULN - Serum creatinine < 1.5 x ULN - PT and PTT normal - Negative pregnancy test - Not pregnant or nursing - Fertile patients must use highly effective contraception - No ischemic heart disease in the past 6 months - 12-lead ECG normal - No history of stroke - No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule - No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of recurrence) - No serious concurrent systemic disorder including any of the following that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol: - Active infection - HIV infection - Cardiac disease - QTc prolongation > 450/470 msec (males/females) - No patients with a congenital long-QT-syndrome in their own or family medical history, unless eligible at the investigator's discretion - No known hypersensitivity to the study treatment - No known hypersensitivity to antihistamines or other medical reason that prohibits the intake of antihistamines - No current alcohol dependence or drug abuse - No legal incapacity or limited legal capacity - Able to undergo a gadolinium-enhanced MRI of the brain PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 4 weeks since prior and no concurrent investigational agent - No prior stereotactic biopsy - At least 30 days since prior drug therapy that has not received regulatory approval for any indication - No chemotherapy within the past 5 years - No prior chemotherapy for a brain tumor - No prior radiotherapy to the head - No other concurrent anticancer therapy - No concurrent anticoagulation therapy except low-dose prophylactic low molecular weight heparin - Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for = 1 week - At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, and phenytoin) - No concurrent strong inducers or inhibitors of CYP3A4 - No concurrent planned surgery for other diseases (e.g., dental extraction) - No placement of Gliadel® wafer during prior surgery |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven | Leuven | |
France | Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau | Nantes-Saint Herblain | |
France | CHU Pitie-Salpetriere AP-HP | Paris | |
Germany | Universitaetsklinikum Freiburg | Freiburg | |
Germany | Universitatsklinikum Heidelberg | Heidelberg | |
Italy | Ospedale Bellaria | Bologna | |
Netherlands | Medisch Centrum Haaglanden - Westeinde | Den Haag | |
Netherlands | Erasmus MC - Daniel den Hoed Cancer Center | Rotterdam | |
Spain | ICO Badalona - Hospital Germans Trias i Pujol | Badalona | |
Switzerland | Ospedale Regionale Bellinzona e Valli | Bellinzona | |
Switzerland | UniversitaetsSpital Zuerich | Zurich | |
United Kingdom | Clatterbridge Cancer Centre NHS Foundation Trust | Bebington | Wirral |
United Kingdom | Western General Hospital | Edinburgh |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC | Pfizer |
Belgium, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival at 1 year | 1 year | ||
Secondary | Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria | end of trial | ||
Secondary | Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years | end of trial | ||
Secondary | Correlation between biomarkers relevant to temsirolimus and PFS and OS | end of trial |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 |